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ABSTRACT
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in many countries is increasing
and, in hospitals in some areas, more than half of all S. aureus disease isolates are MRSA. MRSA strains
are becoming increasingly multiresistant, and have recently developed resistance to vancomycin, used
successfully to treat MRSA for more than 30 years. This review summarises recent studies that have
elucidated the evolutionary history of MRSA. The ﬁrst MRSA isolate evolved from a sensitive, epidemic
strain prevalent in Europe, and its progeny—the ﬁrst MRSA clone—quickly spread to other continents.
Analyses of epidemic MRSA isolates from hospitals in different countries by molecular methods,
including multilocus sequence typing (MLST) and DNA microarray analysis, reveal that MRSA strains
have evolved separately within ﬁve distinct epidemic, sensitive lineages. However, resistance has been
transferred to S. aureus on many more than ﬁve occasions, as some lineages have acquired different
structural types of the element carrying the methicillin resistance gene. The emergence of MRSA as a
community pathogen has been noted in several countries, and MLST and SCCmec typing have been
used to demonstrate that community-acquired MRSA strains are typically related only distantly to
hospital MRSA strains, and thus represent novel acquisitions of SCCmec.
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BACKGROUND
Nosocomial methicillin-resistant Staphylococcus
aureus (MRSA) infections represent a major chal-
lenge to hospital microbiologists because of the
emergence and spread of clones with decreased
susceptibility to many antibiotic classes. Since the
mid to late 1990s, hospital MRSA isolates have
increased in prevalence in Europe, the USA and
elsewhere [1,2]. In one European study of 25
university hospitals [3], one-quarter of 3051
S. aureus isolates collected were MRSA, with a
geographical bias towards higher rates in south-
ern countries such as Italy (50.5%) and Portugal
(54%), and lower rates in northern European
countries, including The Netherlands (2%), Aus-
tria (9%) and Switzerland (2%). MRSA infections
are associated with increased morbidity, mortality
and length of hospital stay, and represent a major
ﬁnancial burden on healthcare services [4,5].
The ﬁrst strain of MRSA was isolated in 1961
[6], 2 years after the introduction of methicillin;
this strain rapidly spread to other countries
throughout the 1960s, and became a problem in
the USA in the 1970s. The antibiotic of choice for
treating MRSA infections is the glycopeptide
vancomycin, but reports of vancomycin interme-
diately susceptible S. aureus (VISA), ﬁrst isolated
in Japan in 1997 [7,8], caused widespread alarm
among physicians fearful of an era of untreata-
ble MRSA infections. Reports of VISA isolates
with an MIC ‡ 8 mg ⁄L have so far been very
rare, but two recent reports of fully vancomycin-
resistant S. aureus (VRSA) from Michigan [9] and
Pennsylvania [10] (MICs of 32 and 128 mg ⁄L,
respectively) in the USA have again caused
alarm, and it is as yet unclear whether either
VISA or VRSA isolates will become epidemic,
leading to an exacerbation of the global MRSA
problem.
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In a climate of increasing S. aureus antibiotic
resistance, the study of MRSA epidemiology has
assumed new importance, because any strategies
to contain the spread of MRSA at the local
(hospital), national or international level require
knowledge of how strains are spread and how
MRSA epidemics occur. Epidemiological studies
can be used to provide basic knowledge of the
population biology of MRSA, and can help to
answer fundamental questions such as: (1) how
strains spread; (2) the number of major MRSA,
VISA and VRSA clones circulating globally, and
their relatedness to each other and to susceptible
isolates; and (3) the ancestry of modern MRSA,
VISA and VRSA strains. The answers to these
questions have, until recently, been unclear, but
several recent studies employing modern molecu-
lar typing technologies have now signiﬁcantly
increased our knowledge in these areas.
MODELS OF MRSA EVOLUTION
Two models of MRSA evolution were initially
proposed in the early 1990s, based on studies
using different typing techniques. The simplest
model, described by Kreiswirth et al. [11], was
based on analysis of restriction fragment length
polymorphisms generated by ClaI digestion of
chromosomal DNA, followed by hybridisation
with Tn554 and mecA probes. The limited number
of patterns observed in a geographical and tem-
porally diverse sample of MRSA isolates was
taken as evidence that S. aureus had acquired the
methicillin resistance gene (mecA) on only one
occasion, and the authors therefore hypothesised
that all extant MRSA clones were recent descend-
ants of this prototypical isolate.
Several months before the publication of this
study, Musser and Kapur [12] described MRSA as
being polyclonal in a multilocus enzyme electro-
phoresis analysis of 254 MRSA isolates. The
association of mecA with divergent genetic back-
grounds was taken as strong evidence that the
gene is transferred horizontally between S. aureus
isolates. The only alternative explanation for these
results was that MRSA isolates had diversiﬁed so
rapidly in the 31 years between 1961 and 1992
that they had lost any genetic similarity. The
existence of modern MRSA lineages that are
unrelated to the ﬁrst MRSA strain by molecular
typing methodologies supports the theory of
Musser and Kapur, and this is further streng-
thened by evidence from microarray analysis [13]
and multilocus sequence typing (MLST) [14] that
conclusively demonstrate horizontal movement
of the mecA gene.
TOOLS FOR INVESTIGATING
CLONAL SPREAD
The recovery of isolates with identical bacterio-
phage types from different hospitals within and
between countries was described in the 1950s in
seminal studies by Rountree and Freeman [15]
and Rountree and Beard [16], in which the
existence of S. aureus types with increased epide-
micity was demonstrated. However, bacterio-
phage typing has fallen out of favour as a
means of characterising S. aureus, because of
difﬁculties in typeability and reproducibility, as
well as the cryptic genetic basis upon which
characterisation relies [17,18].
Molecular typing techniques are commonly
used to study the epidemiology of S. aureus. The
international spread of epidemic clones, such as
the Iberian [19], UK epidemic [20,21], New York–
Japanese [22,23], Viennese [24] and German
MRSA [24], has been investigated with a variety
of techniques, the most popular of which has been
pulsed-ﬁeld gel electrophoresis (PFGE) [25,26].
PFGE is suitable for MRSA outbreak investigation
because of the high level of discrimination attain-
able, which allows outbreak isolates to be separ-
ated from unrelated isolates. The main drawback
of such simple and widely used ‘band-based’
technologies in studying longer-term, national or
global epidemiology is the difﬁculty faced in
making inter-laboratory comparisons of PFGE
data. Standardisation of reagents and electrophor-
esis conditions increases the portability of PFGE,
but subjective decisions about DNA banding
pattern similarity still constitute a major barrier
to establishing PFGE as a satisfactory method for
characterising S. aureus clones.
MLST
MLST [27] involves sequencing DNA fragments
(typically c. 500 bp) of seven housekeeping genes.
The sequences of these genes are compared to
known alleles at each locus via the MLST website
(http://www.mlst.net), where every isolate is
described by a seven-integer allelic proﬁle that
deﬁnes a sequence type (ST). For example, isolates
Robinson and Enright MRSA evolution 93
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 92–97
of the Iberian clone have the MLST proﬁle 3-3-1-
12-4-4-16, which deﬁnes ST247. MLST was ﬁrst
applied to S. aureus in a study published in 2000
[28], in which 155 invasive S. aureus isolates were
typed. In addition to validating the method
against PFGE, the study showed how epidemic
clones of MRSA and methicillin-susceptible
S. aureus (MSSA) could be unambiguously def-
ined by their ST.
SCCMEC TYPING
The methicillin resistance structural gene mecA is
a small (2007 bp) part of a much larger genetic
element which is inserted precisely into the
S. aureus chromosome. This staphylococcal chro-
mosomal cassette mec (SCCmec) varies in size
from c. 20 to 68 kb, but always contains mecA and
at least part of a regulatory gene mecR1 and
chromosomal cassette recombinase genes (ccr).
Four main types of SCCmec have been described
[29,30], and although the same types are often
associated with divergent lineages, particular
MRSA clones are associated with single SCCmec
elements. For example, all epidemic MRSA
(EMRSA) clone 16 (ST36) isolates from the UK
have SCCmec type II (http://www.mlst.net).
MRSA NOMENCLATURE
A report on 912 MRSA and MSSA isolates from 20
different countries [14] contained a proposal that
MRSA clones be named according to their MLST
and SCCmec types in the form ST–resistance
phenotype (i.e., MRSA, MSSA, VISA or VRSA)–
SCCmec type (i.e., I, II, III or IV). For example, the
Iberian clone would be known as ST247-MRSA-I.
This was agreed by a subcommittee of the Inter-
national Union ofMicrobiology Societies in Tokyo,
2002. It is hoped that this nomenclature will
replace, or at least supplement, existing arbitrary
designations of MRSA clones, based on geograph-
ical location or other less satisfactory typing
methods, since MLST is systematic and objective,
and provides a key for investigators to search for
clones in the MLST website databases.
ORIGINS OF THE FIRST MRSA
The ﬁrst study to examine the ancestry of the
original MRSA isolates used MLST to compare
MRSA isolates from different countries with a
collection of MSSA isolates from the 1950s [31].
The study showed that the ﬁrst MRSA clone
belongs to ST250 (allelic proﬁle 3-3-1-1-4-4-16),
which is a genotype shared with epidemic MSSA
isolates common in Denmark in the 1950s. This
‘archaic’ clone was found to be ancestral to the
Iberian clone [19], as it shares six of seven
housekeeping gene alleles. The Iberian clone is a
modern pandemic MRSA that shares the high
epidemicity of the ‘archaic’ clone, a genotype that
spread extremely rapidly after its ﬁrst emergence
in 1961 and was isolated as recently as 1993
(http://www.mlst.net).
The origins of early MRSA isolates were further
clariﬁed in the larger-scale MLST study described
above [14]. In this work, the authors used MLST
and SCCmec typing to show the complexity of
evolutionary events leading to the emergence of
the ﬁrst MRSA isolate and modern epidemic
MRSA and MSSA clones from an ancestral isolate
of ST8 (MSSA) (Fig. 1). The designation of ST8 as
the ancestral genotype was achieved using the
BURST algorithm (based upon related sequence
types; http://155.198.40.150/new/data_analysis/burst/
burst.htm), which separates MLST data sets into
groups called clonal complexes (CCs). These share
at least ﬁve housekeeping gene alleles in common
with at least one other member. For each ST in the
group, the ancestor is assumed to be the genotype
with the largest number of variants differing at
only one gene. The assignment of ST8-MSSA as
the ancestor of ST250-MSSA is supported by the
ﬁnding that ST8 and ST250 differ at a single locus
whose alleles are identical except for a point
mutation in yqiL, unique to ST250 and its descend-
ants [14]. Further support for this hypothesis is the
ﬁnding that all isolates of ST250 and its descend-
ants are MRSA with SCCmec class I. Fig. 1 shows
an evolutionary scenario that could have led to
the emergence of major clones such as ST239-
MRSA-III (named variously as UK EMRSA-1, UK
EMRSA-4, Viennese clone and the Portuguese ⁄
Brazilian clone [32]) and ST247-MRSA-I (the Iber-
ian clone, UK EMRSA-5 and UK EMRSA-17 [33]),
among others.
HOW MANY MRSA CLONES ARE
THERE?
Analysis of a collection of 36 S. aureus isolates by
DNA microarray analysis [13] showed that the
mecA gene was associated with ﬁve genetically
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divergent groups of isolates, indicating that the
gene for methicillin resistance has been horizon-
tally transferred at least ﬁve times in S. aureus. This
ﬁnding was conﬁrmed by an MLST study [14]
which showed that all epidemic hospital MRSA
isolates that have been found in more than one
country belong to ﬁve CCs. These CCs are named
according to the ST of their proposed ancestor,
and include CC8 (archaic MRSA), CC5, which
contains most of the VISA isolates studied to
date, and three clonal complexes (CC45, CC30 and
CC22) that contain recently emerged international
MRSA clones such as UK EMRSA-16 (CC30) [34],
Berlin epidemic MRSA (CC45) [35], and UK
EMRSA-15 or Barnim epidemic MRSA [36].
Major MRSA clones have emerged from some
CCs on multiple occasions, resulting in isolates
with the same MLST type that differ in SCCmec
type. Enright et al. [14] described 11 major epi-
demic MRSA clones, deﬁned as genotypes (same
MLST and SCCmec type), found in more than one
country and represented by at least ten isolates.
This arbitrary designation contains all the epi-
demic MRSA isolates described in the literature,
but the isolates examined are over-representative
of European countries. What is clear from MLST
studies is that a small number of ecologically
successful genetic backgrounds can acquire the
methicillin resistance gene and retain a high level
of epidemicity. This is demonstrated by the fact
that in each of the ﬁve MRSA-containing CCs, the
ancestral genotype is represented by recent dis-
ease-causing MSSA isolates (http://www.mlst.
net).
MRSA strains are emerging as a cause of
community-acquired disease in some countries
but, until recently, the genetic relatedness of such
strains to each other and to hospital MRSA
isolates was not known. Analysis of 47 commu-
nity MRSA isolates from Australia and the USA
[37] by MLST and SCCmec typing showed that
some types are closely related to hospital MRSA,
but that most isolates characterised had STs not
found in studies of hospital MRSA to date.
Isolates of ST1, the most common genotype in
this study, and ST30 have been reported as
common causes of community-acquired MSSA
disease in the past [28], but the acquisition of
SCCmec IV by these successful epidemic geno-
types is worrying, especially as in this study
isolates of these clones expressed Panton–Valen-
tine leukocidin, which in one study was found to
be associated with necrotising pneumonia in
patients with a much younger average age than
is usual for pneumonia [38]. This expansion of the
host range of isolates causing MRSA disease to
the community and to younger age groups is
troubling at a time when the therapeutic options
ST8-MRSA-I
ST8-MSSA ST250-MSSA ST250-MRSA-I
(Archaic)
ST8-MRSA-IV
(EMRSA-2)
ST247-MRSA-I
(Iberian)
ST239-MRSA-III
(EMRSA-I)
ST8-MRSA-II
(Irish-I)
Other MRSA descendants
of ST250 (SCCmec class I)
Fig. 1. Evolutionary origins of nota-
ble CC8 genotypes. Arrows indicate
either (1) acquisition of SCCmec, or
(2) change of ST. For some epidemic
MRSA clones, the name used previ-
ously in the literature is included in
parentheses.
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for the treatment of MRSA are becoming increas-
ingly limited.
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